Evidence map›Paper›PMID 28824540›Full record

ArticleFrontiers in endocrinology2017

Enhanced Mortality to Metastatic Bladder Cancer Cell Line MB49 in Vasoactive Intestinal Peptide Gene Knockout Mice.

Niely Mirsaidi, Matthew P Burns, Steve A McClain, Edward Forsyth, Jonathan Li, Brittany Dukes, David Lin, Roxanna Nahvi, Jheison Giraldo, Megan Patton and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Niely MirsaidiDepartment of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
Matthew P BurnsDepartment of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
Steve A McClainMcClain Laboratories, LLC, Smithtown, NY, United States.
Edward ForsythDepartment of Urology, Stony Brook University School of Medicine, Stony Brook, NY, United States.
Jonathan LiDepartment of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
Brittany DukesDepartment of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
David LinDepartment of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
Roxanna NahviDepartment of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
Jheison GiraldoDepartment of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
Megan PattonThree Village Allergy & Asthma, PLLC, South Setauket, NY, United States.
Ping WangThe Feinstein Institute for Medical Research, Center for Heart and Lung Research, Manhasset, NY, United States.
Ke LinThe Feinstein Institute for Medical Research, Center for Heart and Lung Research, Manhasset, NY, United States.
Edmund MillerThe Feinstein Institute for Medical Research, Center for Heart and Lung Research, Manhasset, NY, United States.
Timothy RatliffPurdue University, Center for Cancer Research, West Lafayette, IN, United States.
Sayyed HamidiJames J. Peters Veterans Affairs Medical Center, Bronx, NY, United States.
Scott CristPurdue University, Center for Cancer Research, West Lafayette, IN, United States.
Ken-Ichi TakemaruDepartment of Pharmacological Sciences, Stony Brook University School of Medicine, Stony Brook, NY, United States.
Anthony SzemaDepartment of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, United States.
Stony Brook University · USCenter for Cancer Research · USFeinstein Institute for Medical Research · USHofstra University · USJames J. Peters VA Medical Center · USNorthwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To identify if the absence of the vasoactive intestinal peptide (VIP) gene enhances susceptibility to death from metastatic bladder cancer, two strains of mice were injected with MB49 murine bladder cancer cells. The growth and spread of the cancer was measured over a period of 4 weeks in C57BL/6 mice and 5 weeks in VIP knockout (KO) mice. A Kaplan-Meier plot was constructed to compare control C57BL/6 mice and C57BL/6 mice with MB49 vs. VIP KO controls and VIP KO mice with MB49. The wild-type (WT) strain (C57BL/6) contained the VIP gene, while the other strain, VIP knockout backcrossed to C57BL/6 (VIP KO) did not and was thus unable to endogenously produce VIP. VIP KO mice had increased mortality compared to C57BL/6 mice at 4 weeks. The number of ulcers between both groups was not statistically significant.

Indexed as

MB49 murine bladder cancermetastasesmortalityvasoactive intestinal peptidevasoactive intestinal peptide gene knockout mice

Identifiers

PMID28824540
PMCPMC5545686
OpenAlexW2742949441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.